Preferred Label : lanadelumab;
CISMeF synonym : DX-2930;
UNII : 2372V1TKXK;
Origin ID : C000596550;
UMLS CUI : C4505508;
ATC code(s)
Currated CISMeF NLP mapping
MeSH term(s) associated for indexing
Record concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3495394/fr/takhzyro-lanadelumab-angioedeme-hereditaire
2024
false
false
false
France
French
insurance, health, reimbursement
lanadelumab
evaluation of the transparency committee
child
angioedemas, hereditary
Hereditary angioedema attack
lanadelumab
treatment outcome
guidelines for drug use
Product containing precisely lanadelumab 150 milligram/1 milliliter conventional release
solution for injection (clinical drug)
---
https://www.has-sante.fr/jcms/p_3498741/fr/takhzyro-lanadelumab-angiooedeme-hereditaire
2024
false
false
false
France
antibodies, monoclonal, humanized
treatment outcome
insurance, health, reimbursement
angioedemas, hereditary
child
lanadelumab
Product containing precisely lanadelumab 150 milligram/1 milliliter conventional release
solution for injection (clinical drug)
Hereditary angioedema attack
evaluation of the transparency committee
lanadelumab
---
https://www.has-sante.fr/jcms/p_3201790
2020
France
evaluation of the transparency committee
lanadelumab
Takhzyro
lanadelumab
---
https://www.has-sante.fr/portail/jcms/c_2973363/fr/takhzyro
2019
false
false
false
France
French
lanadelumab
lanadelumab
injections, subcutaneous
treatment outcome
angioedemas, hereditary
recurrence
adolescent
adult
aged
orphan drug production
evaluation of the transparency committee
lanadelumab
antibodies, monoclonal
---
https://www.ema.europa.eu/en/medicines/human/EPAR/takhzyro
2018
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
lanadelumab
lanadelumab
lanadelumab
orphan drug production
adolescent
adult
angioedemas, hereditary
injections, subcutaneous
plasma kallikrein
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
aged
drug evaluation, preclinical
lanadelumab
lanadelumab
antibodies, monoclonal
antibodies, monoclonal
---